Any news?

[Anonymous]

You didn't read the investor boards, did you, moron? Titan has about $13 million in cash, and Braeburn has to make the decision whether to fund the additional trials or not. The clinical trial results did not establish an equivalent dose for Suboxone/Subutex and the daily dose of buprenorphine received may serve as an agonist but not an antagonist. You don't know much about the drug, halfwit. FDA's concerns were also with the required REMS program. The surgical procedure to remove or insert the rods was also questioned for possible adverse events just like those seen with Norplant while it was still on the market.

And yes, I did read ALL of the available boards. Most of them were duplicates, so if you read even the first ten entries on Google, you would know that.

Next time try actually doing some background research before you shoot off your ignorant mouth. Either this product is dead in the water or it will take more time and money than Braeburn or Titan might be willing to spend.

Troll. Does your spouting off make you feel better? You are rehashing the adcom brief. You've been hanging around the methadone clinics too long.

 

[Anonymous]

Troll. Does your spouting off make you feel better? You are rehashing the adcom brief. You've been hanging around the methadone clinics too long.

What happened? Thought you were going to get a good offer to sell that product? Did it fall through? Poor widdle Reckitt refugee...

 

[Anonymous]

Any word as to why it was developed as a multi implant vs maybe 1 or 2? The technology exists.

 

[Anonymous]

Any word as to why it was developed as a multi implant vs maybe 1 or 2? The technology exists.

From what the RD-2-B said, there was some kind of limit to the releasing technology. Don't know if that was BS or not, but it no longer matters.

 

[Anonymous]

??? Will it get approved

 

[Anonymous]

??? Will it get approved

No it is still stuck in traffic.

 

[Anonymous]

Here's some news on the competition...

Federal agents raid pharmaceutical company’s Chesterfield office
Posted on: 1:46 pm, December 3, 2013, by Web Staff and Joe St. George, updated on: 09:18am, December 4, 2013
CHESTERFIELD COUNTY, Va. (WTVR) – Federal agents raided the Midlothian office of Reckitt Benckiser Pharmaceuticals Tuesday. The office is in the Fairfax Building located at 10710 Midlothian Turnpike.
“We can confirm that federal officers from the US government presented a search warrant at the offices of Reckitt Benckiser Pharmaceuticals, Inc.,” company spokesman Tony Brand wrote in an email. “RB is cooperating fully with the investigation, but the officials did not disclose the purpose of the warrant.”
The raid involved the Internal Revenue Service (IRS), the Food and Drug Administration and Office of Inspector General (OIG), according to CBS 6 reporter Joe St. George who was on the scene. OIG is part of part of the U.S. Dept. of Health and Human Services.
“People who work in the building say it is a pharmaceutical company getting raided,” St. George tweeted. [Click here to follow Joe on Twitter]
Federal officials on site did not comment regarding the specifics of the raid.
According to its website, RB is an international company specializing in health and consumer items, although its Chesterfield office dealt exclusively with pharmaceutical drugs.
Reuters reported in November that the company was considering selling its pharmaceutical unit.
The New York Times reported earlier this year the FDA asked the Federal Trade Commission to investigate the company’s potentially anti-competitive business practices.
It is unclear whether or not Tuesday’s raid was related to that request or not.
RB’s office occupies just one small part of the medical office building.
Employees in other parts of the building reported the work day for them was relatively a smooth one with investigators focusing solely on RB’s office.
Photo Gallery Expand 1 of 3

IRS raids 10710 Midlothian Turnpike (PHOTO: Joe St. George)

 

[Anonymous]

not yet

 

[Anonymous]

Anyone who goes into that PDI contract will have to have addiction medicine experience, like a displaced Reckitt rep or someone who worked for Alkermes with Vivitrol. If you don't know addiction medicine, you can't just walk in and try to sell them. All of the addiction practitioners, whether addiction medicine or addiction psychiatrists, know each other and they communicate a lot. One bad detail will get around quick. One bad detail and you'll lose all credibility. It's not an area where you can wing it, because the prescribers will nail you on the spot.

Priorities little pony. Warm lunches and orderly sample closets equal big success in this world.

I will take note. Clearly, not aware the importance the job carries.

 

[anonymous]

Braeburn Pharmaceuticals, a phase III specialty pharmaceutical company, focuses on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain, and schizophrenia. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges.